Article

Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in LMIC: a molecular diagnostics study

Sukripong Pakdeerat[1] Bsc; Phumrapee Boonklang[1] Bsc; Kesorn Angchagun[1] Bsn; Chalita Chomkatekaew[1] Msc; Yaowaret Dokket[1] Bsc, Areeya Faosap[1] Bsc, Gumphol Wongsuwan[1] Msc; Vanaporn Wuthiekanun[1] Bsc, Panatda Aramrueung[2] Msc; Phadungkiat Khamnoi[3] Bsc; Hathairat Thananchai[4] DPhil; Suwattiya Siriboon[5] MD; Parinya Chamnan[5,6] MD, PhD; Sharon J Peacock[7] MD, PhD; Nicholas PJ Day[1,8] MD; Nicholas R Thomson[9] PhD; Chayasith Uttamapinant[10] PhD; Claire Chewapreecha[1,9,11] PhD*; Somsakul Pop Wongpalee[4] PhD*

Affiliations:

1. Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
2. Central Laboratory, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand
3. Diagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
4. Department of Microbiology, Faculty of Medicine, Chiangmai University, Chiang Mai, Thailand
5. Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand
6. Ministry of Public Health, Nonthaburi, Thailand
7. Department of Medicine, University of Cambridge, UK
8. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
9. Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, UK
10. School of Biomolecular Science and Engineering, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong, Thailand
11. Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

*Indicates equal contribution and corresponding authors: claire@tropmedres.ac and somsakul.w@cmu.ac.th

32 **Summary**

33 **Background**

34 Melioidosis is a grossly neglected but often-fatal tropical disease. The disease is named "a great
35 mimicker" after its broad clinical manifestations, which makes disease diagnosis challenging and
36 time-consuming. To improve diagnosis, we developed and evaluated the performance of the
37 CRISPR-Cas12a system called "CRISPR-BP34" to detect *Burkholderia pseudomallei* DNA across
38 clinical specimens from patients suspected to have melioidosis.

39 **Methods**

40 We documented time taken for diagnosis, antibiotics prescribed during the waiting period, and
41 infection outcomes in 875 melioidosis patients treated in a hospital in northeast Thailand between
42 October 2019 and December 2022. In the last six months, we performed CRISPR-BP34 detection
43 on clinical specimens (blood, urine, respiratory secretion, pus and other body fluids) collected from
44 330 patients with suspected melioidosis and compared its performance to the current gold-standard
45 culture-based method. Discordant results were validated by three independent qPCR tests.

46 **Findings**

47 A window of 3-4 days was required for gold-standard culture diagnosis, which resulted in delayed
48 treatment. 199 [22·7%] of 875 patients died prior to diagnosis results while 114 [26·3%] of 433
49 follow-up cases had been diagnosed, treated, but died within 28 days of admission. A shorter
50 sample-to-diagnosis time of less than 4 hours offered by CRISPR-BP34 technology could lead to
51 faster administration of correct treatment. We demonstrated an improved sensitivity of CRISPR-
52 BP34 (106 [93·0%] of 114 positive cases, 95% CI 86·6 - 96·9) compared to the culture approach
53 (76 [66·7%] of 114 positive cases, 95% CI 57·2 - 75·2); while maintaining similar specificity (209
54 [96·8%] of 216 negative cases, 95% CI 93·4-98·7) to the culture (216 [100 %] of 216 negative
55 cases, 95% CI 98·3-100·0).

56 **Interpretation**

57 The sensitivity, specificity, speed, window of clinical intervention, and ease of operation offered
58 by the CRISPR-BP34 support its use as a point-of-care diagnostic for melioidosis.

59 **Funding**

60 Chiang Mai University Thailand and Wellcome Trust UK

Research in context

Evidence before this study

Melioidosis is an often-severe infectious disease caused by the bacterium *Burkholderia pseudomallei*. It is estimated to affect 165,000 individuals annually worldwide, of which 89,000 cases are fatal. The disease diagnosis is challenging due to diverse clinical presentations, low awareness, limited diagnostic options, or even a lack of diagnostic tests. A PubMed search conducted from the database inception to 6 May 2023, using the terms “melioidosis” AND “diagnosis test,” yielded 207 results, 40 of which presented clinical evaluations of rapid melioidosis diagnostic tests. Antigen-based diagnostic tests, which detect the presence of *B. pseudomallei*, reported high specificity (median = 98·6%, IQR 94·0 - 100·0), but low sensitivity (median = 57·1%, IQR = 44·3 - 82·5). The test sensitivity suffers from the often-low concentration of the bacterial antigens in patients' samples, which can vary by specimen type and stage of infection. Antibody-based diagnostic tests that detect host antibodies against *B. pseudomallei* typically exhibit satisfactory specificity (median = 94·5%, IQR = 88·6 - 96·2) but poor sensitivity (median = 80·2%, IQR = 71·0 - 88·1). These tests are often impacted by variations in antibody responses to *B. pseudomallei* and the duration required for antibody production. Furthermore, standardisation remains challenging due to the influence of different serum titres on sensitivity and background of the tests. Likewise, quantitative PCR exhibits a high degree of specificity (median = 99·8%, IQR = 91·6-100·0), but an observed low sensitivity for melioidosis (median = 77·1%, IQR = 20·8-97·8), which is likely attributed to the genetic heterogeneity of *B. pseudomallei* genomes. Additionally, these studies consistently reported a demand for improved speed and ease of implementation in resource-limited settings where melioidosis is endemic. With the limitations of current diagnostic methods, a culture-confirmed approach with 60% sensitivity, 100% specificity, and a diagnosis time of 2-7 days still stands as the gold standard for melioidosis diagnosis.

Added value of this study

To date, no study has measured the impact of delayed diagnosis on melioidosis. We assessed the number of deaths occurring prior to culture-confirmed diagnosis (22·7%) and those after diagnosis but within 28 days post-admission (26·3%), highlighting the urgent need for prompt action. To address this, we developed the CRISPR-BP34 test, which utilises isothermal amplification of a nucleic acid target followed by site-specific detection using a CRISPR-Cas12a

92 enzyme. We successfully implemented this assay in a resource-limited setting in northeast
93 Thailand, where the disease prevalence is among the highest in the world. The assay achieved a
94 diagnostic sensitivity and specificity of 93·0% and 96·8%, respectively, with a limit of detection
95 ranging from 50-250 cfu/mL. Early diagnosis can be achieved within four hours of patient
96 admission, which is significantly faster than the gold-standard test that typically takes several days.
97 Moreover, the ultrasensitivity of the CRISPR-BP34 assay enabled the detection of low levels of
98 *B. pseudomallei* in hemoculture bottles, which could be missed due to mixed infections, poor
99 aseptic technique, or other causes, leading to undiagnosed melioidosis.

100 **Implications of all available evidence**

101 The CRISPR-BP34 test holds great promise for the management and control of
102 melioidosis. Its minimal setup and shallow learning curve make it well-suited for resource-limited
103 settings. Additionally, its speed and high sensitivity enable early diagnosis and treatment, which
104 are crucial for saving patients' lives.

105 **INTRODUCTION**

106 Melioidosis is a neglected tropical disease with a high case-fatality (10-50%) even when
107 appropriately treated[1]. The global disease burden expressed in disability-adjusted life-years
108 (DALYs) is 4·64 million, 99% of which is accounted for by years of life lost (YLL)[2]. High
109 mortality may be explained by the disease disproportionately affecting rural populations in low-
110 and middle-income countries (LMICs)[3], many of which have poor socioeconomic conditions and
111 often present to healthcare facilities in a terminal or critical phase of the disease[4]. Melioidosis is
112 caused by *Burkholderia pseudomallei*, an environmental bacterium in soil and water across the
113 tropical regions of Asia Pacific[5], South[6] and Southeast Asia[7]. However, the disease remains largely
114 underreported due to its non-specific clinical manifestations that can "mimic" several other
115 diseases. A lack of disease awareness in clinics and communities as well as the paucity of
116 diagnostic facilities leads to missed or delayed diagnosis. With early diagnosis and appropriate
117 treatment the mortality rate from melioidosis can be decreased to less than 10%[5].

118 Clinical specimens from patients with suspected melioidosis are typically screened for the
119 presence of *B. pseudomallei* using microbial culture, which has been the gold standard diagnostic
120 method for the last three decades. This method is imperfect, with a specificity of 100% but a
121 sensitivity of 60%[8]. *B. pseudomallei* grows more slowly in the laboratory compared with other
122 pathogens[9], which can lead to over-growth by other bacteria or fungi present in the sample as part
123 of a mixed infection and/or contamination. This can result in failure to detect *B. pseudomallei*. If
124 cultured successfully, *B. pseudomallei* colonies can be easily misinterpreted as environmental
125 contaminants, and correct identification requires an expert microbiologist. Moreover, a combined
126 time to grow and identify *B. pseudomallei* may take up to 7 days, which inevitably delays the
127 disease diagnosis[8]. Culture-free antigen-based and nucleic acid-based tests such as a lateral flow
128 immunoassay (LFI)[10], an immunofluorescence assay (IFA)[11], polymerase chain reaction (PCR)[12–
129 14], or 16S rRNA sequencing[15] have been developed for the diagnosis of melioidosis. However, the
130 heterogeneity in bacterial concentrations[16,17] across clinical specimens leads to a limited sensitivity
131 of 58·2% (95% CI, 34·1 – 78·9%) for LFI[18] and 63·8% (45·6 – 78·7%) for IFA[18]; whilst tests that
132 offer higher sensitivity require thermal cyclers or sequencing machines[15], which are rarely
133 available in rural settings.

134 An improved sensitive and specific detection of *B. pseudomallei* DNA in a range of sample
135 types using field-deployable equipment has the potential to improve the diagnosis of melioidosis.

136 This can be achieved by first amplifying DNA of the pathogen using recombinase polymerase
137 amplification (RPA), followed by sequence-specific recognition of clustered regularly interspaced
138 short palindromic repeats (CRISPR)-Cas12a endoribonuclease at the DNA target. This approach
139 has been applied to other bacterial pathogens including *Mycobacterium tuberculosis*[19] and has
140 been demonstrated to improve diagnosis and treatment responses. We previously described a
141 robust CRISPR-based detection of genomic DNA of *B. pseudomallei in vitro*[20]. Here, we
142 addressed the issues surrounding delayed diagnosis of melioidosis, established a diagnostic
143 protocol for our recently developed CRISPR-Cas12a system (here-after termed CRISPR-BP34)[20],
144 and determined its diagnostic sensitivity and specificity. Our results showed higher sensitivity and
145 shortened diagnostic time of the CRISPR-BP34 detection compared with the gold standard culture.
146

147 **METHODS**

148 **Study design and patients**

149 Two related studies were conducted and reported here. Study 1 quantified the time taken
150 to diagnose melioidosis based on culture and patient outcome, and Study 2 evaluated the diagnostic
151 performance of the CRISPR-BP34 assay (Figure 1).

152 Study 1 was a prospective observational cohort study of patients with culture-confirmed
153 melioidosis at Sunpasitthiprasong Hospital, a tertiary care hospital in Ubon Ratchathani, Thailand
154 between October 2019 and December 2022 (Figure 1A, appendix p 3). Study objectives were to
155 assess the disease prevalence, the time taken to reach a diagnosis of melioidosis, the empirical
156 antibiotics prescribed prior to diagnostic confirmation, and patient survival during 28-day follow-
157 up from the admission date. Routine clinical practice was to obtain blood, urine, respiratory
158 secretions and fluid (sputum, tracheal suction, pleural fluid), and other body fluid and tissue as
159 available (pus, limb tissue, and synovial fluid) for culture from patients with suspected melioidosis.
160 All samples were collected according to WHO guidelines[21]. The standard culture methods used
161 for each specimen type are outlined in the appendix (p 5). All patients with culture-confirmed
162 melioidosis were identified through the hospital computer. The length of time between sampling
163 and culture result was recorded for each patient. Cases who remained alive when the culture result
164 become available were visited to obtain written consent to collect clinical information. 875 culture-
165 confirmed melioidosis cases were identified, of whom 433 were alive at the time of culture
166 confirmation and gave written consent to obtain and use clinical information on antibiotic

167 treatment and 28-day outcome (Figure 2). The study received ethical approval from the
168 Sunpasitthiprasong Hospital Ethical Review Board (015/62C) and the Oxford Tropical Research
169 Ethics Committee (OxTREC, 25-19). This study is registered with Thai Clinical Trial Registry
170 (TCTR20190322003).

171 Study 2 was a diagnostic evaluation of the sensitivity and specificity of a CRISPR-BP34
172 prototype assay[20] conducted at Sunpasitthiprasong Hospital between May 2022 and December
173 2022 (Figure 1B). Minimal sample size was determined using the formula $n = z^2 p(1-p) / d^2$ where
174 "z" is the 95% confidence interval at 1·96; "p" is the prevalence at 0·5; and "d" represents the
175 margin of error at 0.1. At least 96 melioidosis and 96 non-melioidosis patients were required for
176 the CRISPR-BP34 diagnostic test. Specimens were collected from patients with suspected
177 melioidosis (appendix p 3) at the time of hospital presentation for culture identification. 1 mL of
178 leftover sample from the culture was obtained from the hospital microbiology laboratory and
179 stored at -20 °C for CRISPR-BP34 screening. Once the culture results arrived (appendix p 5), a
180 head-to-head CRISPR-BP34 assay (appendix pp 6 & 10-19) was performed. In total, the study
181 examined 114 melioidosis and 216 non-melioidosis patients, which were sampled across four
182 different specimen types: blood (41 and 74 samples), respiratory secretions and fluids (52 and 54
183 samples); urine (27 and 71 samples), and other body fluids and tissues (15 and 30 samples) from
184 melioidosis and non-melioidosis patients, respectively. The study received ethical approval from
185 the Ethical Review Board of Sunpasitthiprasong Hospital (029/65C).
186

187 **Determining the molecular sensitivity of CRISPR-BP34 assay *in vitro***

188 To determine the limit of detection of the CRISPR-BP34 assay, we conducted *in vitro*
189 experiments by inoculating genetically modified *Escherichia coli* that harbors a target DNA of the
190 CRISPR-BP34 in its genome (appendix p 4) into blood and urine samples from a single healthy
191 donor at different concentration ranging from 0, 10, 50, 100, 250, 500, 2500 and 5000 cfu/mL.
192 Two to five biological replicates were performed for each experiment. CRISPR-BP34 detection
193 was performed on blood as described in the appendix (p 6). Blood and urine were selected to
194 represent the most common types of clinical specimens processed from patients with suspected
195 melioidosis. The use of the modified *E. coli* as a surrogate for *B. pseudomallei* was to circumvent
196 laboratory safety requirement.
197

198 **Clinical evaluation of CRISPR-BP34 assay**

199 Different types of clinical sample require specific sample preparation due to the variable
200 amounts of target bacterial cells[16], host cells and inhibitors present in each sample. Further details
201 of how the assay was performed on each sample type is described in the appendix (pp 6-8). For
202 each clinical sample, human cells were first depleted using a simple buffer system to selectively
203 lysed human cells, leaving a pellet of bacterial cells. Bacterial genomic DNA was then extracted
204 from the pellet using either hot alkaline lysis or a spin column, depending on the pellet size. *B.*
205 *pseudomallei* DNA was amplified in an RPA reaction, and the resulting amplicons were added
206 into a 50-µL CRISPR reaction, comprising of CRISPR RNA (crBP34)[20], LbCas12a protein and
207 FAM-biotin probes. This reaction was incubated at 37 °C for 60 minutes, after which a
208 HybriDetect lateral flow dipstick (TwistDx, UK) was directly immersed into the reaction and
209 allowed to develop for 5 minutes before reading by eye. A positive result was defined as the
210 appearance of an upper band (anti-IgG) on the dipstick. The assay was performed in a batch of 10
211 samples with each batch comprising of culture positive and negative samples to avoid batch effect.
212 For all batches, *B. pseudomallei* positive sample and distilled water were used as positive and
213 negative controls, respectively. The sample-to-result time was recorded. The CRISPR-BP34
214 results were interpreted by three different readers who were blinded to the patient disease status
215 and culture results.

216 Not every sample cultured from a melioidosis patient yields positive result, a scenario
217 driven by different local concentration of *B. pseudomallei*. Discordant results between culture and
218 the CRISPR assay were tested by quantitative PCR (qPCR) using three primer sets listed in the
219 appendix (pp 8, 21 & - 23). Given a large discrepancy in reported diagnostic sensitivity of PCR
220 primers[18] and a high sequence diversity of *B. pseudomallei*, the use of primer combinations
221 ensured an increased coverage of the detection. The qPCR cycle threshold (ct) values were
222 recorded and used as a proxy for bacterial loads.

223

224 **Statistical analysis**

225 All numerical data was summarised using medians, interquartile ranges (IQR), and
226 proportion. For comparison with non-parametric distribution, wilcoxon signed-rank tests were
227 used with Benjamini-Hochberg correction for multiple testing. The culture and CRISPR-BP34
228 results from the same specimen were compared against the patient's disease status. Sensitivity and

229 specificity were defined as TP/ (TP + FN) and TN/ (TN + FP), respectively. "TP" and "FN"
230 represent the number of cases that tested positive and negative in the disease group, respectively.
231 "TN" and "FP" are the number of cases that tested negative and positive in the non-disease group,
232 respectively. The sensitivity and specificity were separately calculated for culture and CRISPR by
233 sample type (grouped into four categories: blood; urine; respiratory secretion; and pus, tissue and
234 other body fluid), and by total specimens. For a patient who had multiple samples taken, only the
235 earliest sample was included for sensitivity and specificity calculations. The exact 95% confidence
236 interval was estimated using Clopper-Pearson Binomial assumption[30].
237

238 **RESULTS**

239 **Current time to diagnosis, empirical antibiotic treatment, and outcomes**

240 Of 875 culture-confirmed melioidosis patients admitted or referred to Sunpasitthiprasong
241 Hospital during October 2019 to December 2022, 199 died before the culture results arrived
242 (Figure 1A). Among 433 patients who survived to culture results and consented to participate in
243 our study, 114 patients died within 28 days after first presentation to Sunpasitthiprasong hospital.
244 The minimum fatality of 35·8% based on the combined data is consistent with 35% mortality
245 reported in Thailand[22]. A relatively high fatality reported in this setting could be attributed to
246 socioeconomic disparity[2] which impacted mostly agricultural workers (272 [62·8%] of 433
247 patients) who lived on average 65 km (IQR 40 – 100 km) from the culture-confirmed diagnosis
248 facility (Table 1). Melioidosis patients displayed diverse clinical manifestations with persistent
249 fever being the most common symptom (Table 1, appendix p 22). Patients experienced symptoms
250 for a median of seven days (IQR 3 -14 days) before seeking medical care at the local or central
251 health-care centres, which subsequently referred them to Sunpasitthiprasong hospital within one
252 day (IQR 0 – 4 days). Multiple samples were collected from patients for culture diagnosis upon
253 first admitted or referred, and during their stay at Sunpasitthiprasong hospital as clinically
254 indicated. The median duration between the first sample collection and the first positive culture
255 result was four days (IQR 3 - 5 days), at which point melioidosis diagnosis was confirmed.
256 Notably, the time from symptom onset to diagnosis averaged 16 days (IQR 9 – 27 days), although
257 this differed significantly between patients who died (12 days, IQR 7 – 19 days) and those who
258 survived (18 days, IQR 10 – 31 days, wilcoxon test p-value = $5{\cdot}62 \times 10^{-5}$), underscoring the need
259 for prompt clinical intervention to avert fatal outcomes.

260 In Thailand, patients suspected of having melioidosis are recommended to receive empiric
261 treatment with intravenous ceftazidime or a carbapenem antibiotics, such as meropenem or
262 imipenem, for initial intensive monotherapy[23]. Antibiotic administration data was available for
263 433 patients of which 49 (11·3%) and 54 (12·5%) respectively received ceftazidime or a
264 carbapenem monotherapy upon their first presentation to Sunpasitthiprasong hospital (Figure 2A,
265 Table 1). The remainder received other treatments including a monotherapy or combinations of
266 antibiotics known to be ineffective in treating melioidosis such as lincosamides[24], macrolides[24,25],
267 penicillin[25] and first- and second-generation cephalosporin[24,26], and ineffective third-generation
268 cephalosporins such as ceftriaxone[27]; an inevitable practice to cover the broad spectrum of
269 infection when the causative agents were unknown (Figure 2B & C, appendix p 22). A lower
270 mortality (5 [10·2%] of 49) was observed in patients who received ceftazidime monotherapy than
271 in patients who received other types of treatments (109 [28·5%] of 382; Fisher's exact p-value
272 $5·42 \times 10^{-3}$, Table 1). To increase the use of ceftazidime monotherapy at first presentation from
273 11·3% to 100%, a more rapid diagnosis will be necessary.
274
275 **Clinical evaluation of the CRISPR-BP34 assay**
276 We developed the CRISPR-BP34 assay to detect *B. pseudomallei* DNA, which
277 demonstrated high sensitivity and specificity *in vitro*[20]. We tested the limit of detection of the
278 CRISPR-BP34 by spiking blood and urine samples and found it to be 250 cfu/mL and 50 cfu/mL,
279 respectively (Figure 3A & B). To determine whether CRISPR-BP34 test is sufficiently sensitive
280 to detect the bacterium across various clinical samples, we enumerated the numbers of *B.*
281 *pseudomallei* recovered from different specimen types using both new experiments and previous
282 datasets[16,17] (Figure 3C). Our results showed that the number of *B. pseudomallei* detected in most
283 common specimens such as urine (median = $2·6 \times 10^4$ cfu/mL, sputum (median = $8·8 \times 10^7$
284 cfu/mL), pus and other body fluids (median = $5·4 \times 10^7$ cfu/mL) were greater than the CRISPR-
285 BP34 limit of detection. Since direct blood samples had a lower *B. pseudomallei* concentration
286 (median = 1·5 cfu/mL) than the limit of detection, we substituted direct blood samples with
287 hemoculture positive samples (median = $7·3 \times 10^7$ cfu/mL) to ensure sufficient bacterial
288 concentration. Hemoculture positive samples are blood samples that have been incubated in a
289 culture medium to allow the bacterium to grow, but at this point, the bacterium's identity remained
290 unknown (Figure 3D).

291 We tested the hypothesis that CRISPR-BP34 assay would be more sensitive and faster than
292 culture-confirmed approach in clinical samples collected from 114 melioidosis and 216 non-
293 melioidosis patients. Of these, 20 melioidosis and 12 non-melioidosis patients had samples
294 collected across multiple specimen types (Figure 4A), while 94 melioidosis and 204 non-
295 melioidosis patients had a single sample type collected (Figure 4B). Using first sample available
296 from each patient, we estimated the overall diagnostic sensitivity and specificity of both methods.
297 Our findings showed an overall sensitivity of CRISPR-BP34 of 93·0% (106 of 114 samples, 95%
298 CI 86·6 – 96·9), higher than the sensitivity of culture at 66·7% (76 of 114 samples, 95% CI 57·2
299 - 75·2) (Figure 4C, Table 2). The overall specificity of the CRISPR-BP34 was 96·8% (209 of 216
300 samples, 95% CI 93·4 - 98·7), compared to 100% (216 of 216 samples, 95% CI 98·3 - 100) for
301 culture (Figure 4D, Table 2). Sensitivity of CRISPR-BP34 versus culture for individual sample
302 types was generally higher for CRISPR-BP34, as follows: hemoculture at 100% (41 of 41 samples)
303 vs 58·5% (24 of 41 samples); urine at 70·4% (19 of 27 samples) vs 51·9% (14 of 27 samples);
304 respiratory secretions and fluids at 94·2% (49 of 52 samples) vs 84·6% (44 of 52 samples); and
305 other body fluids and tissue at 100% (15 of 15 samples) vs 73·3% (11 of 15 samples) in CRISPR-
306 BP34 (Figure 4C and Table 2). Specificity of CRISPR-BP34 versus culture for individual sample
307 types was equivalent or slightly lower for CRISPR-BP34, as follows: hemoculture at 94·6% (70
308 of 74 samples) vs 100% (74 of 74 samples); urine at 98·6% (70 of 71 samples) vs 100% (71 of 71
309 samples); respiratory secretions and fluids at 98·2% (53 of 54 samples) vs 100% (54 of 54
310 samples); and other body fluid and tissue at 98·67% (29 of 30 samples) vs 100% (30 of 30 samples)
311 in CRISPR-BP34 and culture assay, respectively (Figure 4D and Table 2).
312
313 In addition, the CRISPR-BP34 assay provided faster results and significantly reduced the
314 turnaround time for all sample types compared to culture approach (Figure 5A). The average
315 sample-to-diagnosis time for culture approach was 2 – 4 days for hemoculture, 4 days for urine,
316 and 4 – 6 days for respiratory secretion and fluids, as well as other body fluids and tissues. In
317 contrast, the average diagnostic time for the CRISPR-BP34 assay was 1 – 3 days for hemoculture
318 and 4 hours for urine, respiratory secretion, and fluids, as well as other body fluids and tissues.
319
320 **Potential use case**

321 20 of 114 melioidosis patients had multiple sample types, as well as multiple numbers of
322 samples per type collected over time (Figure 4A, Figure 5), enabling investigation of how each
323 patient was diagnosed and treated in the real world. Early specimens were collected on the first or
324 within a few days of admission or referral to aid disease diagnosis, while late specimens were
325 taken at 3-, 5- or 7-days intervals following antibiotic prescription to assess response to the
326 treatment. A proportion of early specimens taken from patients who were later confirmed to have
327 melioidosis were culture negative. This could be either attributed to the concentration of *B.*
328 *pseudomallei* being lower than the culture limit of detection, or contamination of the samples with
329 other fast-growing bacterial species (Figure 5B to D). One striking example was a hemoculture
330 bottle from a melioidosis case presented in Figure 5C, which was contaminated with coagulase-
331 negative staphylococci, a skin commensal. The CRISPR-BP34 assay, however, reported *B.*
332 *pseudomallei* positive from this contaminated blood bottle, consistent with subsequent qPCR
333 experiments confirming the presence of *B. pseudomallei* DNA and with patient's final diagnosis.
334 We observed a high cycle threshold (ct) score of *B. pseudomallei* in the contaminated hemoculture
335 bottle and other contaminated samples (median = 32·3, IQR 30.5 - 35·9), compared to average ct
336 values detected in *B. pseudomallei* positive hemoculture (median = 14·0, IQR 13·4 - 14·9,
337 appendix p 21). This likely indicates that the *B. pseudomallei* population was outcompeted by
338 contaminant species. Cross-contamination incidents like this are not uncommon in laboratories
339 with limited resources such as in rural Thailand which could result in an underestimation of the
340 true incidence of melioidosis[28]. Regardless, for all cases being followed, CRISPR-BP34 provided
341 earlier identification of *B. pseudomallei* than the culture method (Figure 5B to D).
342
343 **DISCUSSION**
344 The first part of our study documented the time taken from first melioidosis symptom-to-
345 diagnosis, the empirical treatment patients received during diagnosis uncertainty, and death that
346 occurred prior or after the arrival of culture-confirmed diagnosis result. We noted that many
347 severely ill patients died before we could reach them, thereby introducing survival bias in our
348 study. Nevertheless, our findings echo the problems of delayed disease diagnosis, and imperfect
349 treatment during diagnosis uncertainty, which may separately, or collectively contribute to death.
350 To improve the appropriate and timeous initiation of melioidosis treatment, we developed an easy
351 to implement point-of-care CRISPR-BP34 assay (appendix pp 7-19), tested the sample-type

352 specific protocols (Figure 3C), and evaluated the test performance (Figure 4) in the second part of
353 our study. To our knowledge, a lower limit of detection at the range of 50 – 250 cfu/mL is the
354 highest among reported melioidosis rapid diagnosis tests without requiring extensive equipment
355 such as a qPCR machine or a UV microscope. For common clinical specimens with high bacterial
356 loads (over 10^3 cfu/mL) such as hemoculture samples, genitourinary fluids, respiratory secretions,
357 and pus and other body fluids; CRISPR-BP34 could be used on DNA extracted from these direct
358 samples. This resulted in high level of sensitivity of the CRISPR-BP34 test of 93·0% compared to
359 66·7% sensitivity for overall samples of culture approach (Figure 4C). We cautioned the use of
360 CRISPR-BP34 in samples with very low bacterial loads. Although CRISPR-BP34 could detect the
361 presence of *B. pseudomallei* at the concentration as low as 50 cfu/mL, the miniscule volume of
362 specimens utilised by the CRISPR approach means that the test can be skewed by inaccurate
363 pipetting or handling errors. Thus, for direct blood samples, we recommend using CRISPR-BP34
364 on DNA extracted from hemoculture (enriched media) instead of direct blood samples to maintain
365 high sensitivity.

366 We also observed a slight drop in the CRISPR test specificity being 96.8% compared to
367 100% specificity of culture approach across all sample types (Figure 4D). Some of the "false"
368 positives could be "true" but "missed" diagnosis cases as result of current imperfect diagnosis
369 techniques including culture-confirmed approach[8] and qPCR[18] with suboptimal primers. Some
370 "false" positives may arise when high copy numbers of genetic materials or RPA amplicons were
371 mixed or handled in a confined bench setting, which is sometimes unavoidable in crowded space
372 of resource-limited laboratories. Alternatively, the CRISPR-BP34 complex may mistakenly target
373 other DNA sequences, resulting in false positives. However, the latter is likely mitigated by the
374 double-layered specificity provided by RPA primers and CRISPR RNA; each of which were
375 carefully designed using the genomic database of over 40,000 bacterial and human DNA[20]. To
376 ensure robust test, suggestions to minimise the DNA cross-contamination which could generate
377 false positives were fully documented in the appendix (p 8).

378 In summary, the CRISPR-BP34 test has exhibited higher sensitivity and comparable
379 specificity to the gold standard culture-confirmed method, with more rapid detection capabilities
380 across various types of clinical specimens. Our findings provide preliminary evidence to support
381 the use of the CRISPR-BP34 test as a point-of-care diagnostic tool. Its implementation could lead
382 to prompt initiation of lifesaving treatment (Figure 5B to E), with use cases discussed and

383 positively received by Ministry of Public Health Thailand and regional health authorities[29]. Further
384 research into multiplexing the CRISPR-BP34 test with other genetic biomarkers for antibiotic
385 resistance to guide treatment is a tantalising subject for investigation, as this could potentially
386 provide more targeted treatment options for individuals with melioidosis.

387 **Contributors**

388 CChe and SPW conceived the study and secured funding. PC, SS, CU, HT, CChe and SPW,
389 designed the study. SP, PB, KA, YD, AF, GW, PA, PK, VW, and CCho were involved in study
390 implementation under CChe and SPW supervision. CChe and SPW did the analysis. CChe, SPW,
391 PC, SJP, NPJD, NRT, and CU interpreted the data. CChe and SPW wrote the first draft. All authors
392 read and approved the manuscript.

393

394 **Data sharing**

395 Deidentified participant data that underlie the results reported in the article will be made available
396 upon request. Proposals should be directed to the corresponding author, claire@tropmedres.ac.
397 Proposals will be reviewed and approved by the sponsor on the basis of compliance with the
398 informed consent and scientific merit.

399

400 **Acknowledgements**

401 SPW was funded by TSRI Fundamental Fund 2022, Chiang Mai University (grant number
402 65A104000009) and Faculty of Medicine Research Fund, Chiang Mai University (grant number
403 MIC-2562-06372). CCho was funded by Wellcome International Master Fellowship
404 (221418/Z/20/Z). CChe was funded by Wellcome International Intermediate Fellowship
405 (216457/Z/19/Z) and Sanger International Fellowship. This research was funded in whole, or in
406 part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY
407 public copyright licence to any Author Accepted Manuscript version arising from this submission.

408

409 **Role of the funding source**

410 The funders of the study had no role in study design, data collection, data analysis, data
411 interpretation, or writing of the report.

412 **Figure legends**

413 **Figure 1: Study design: A** summarises the mortality of melioidosis patients who were admitted
414 or referred to Sunpasitthiprasong Hospital between October 2019 and December 2022. All cases
415 were identified by culture-confirmed diagnosis, which commonly arrived on day 4. A substantial
416 number of patients died prior to the arrival of the gold-standard test result. **B** presents our case-
417 control study to evaluate the use of CRISPR-BP34 as an alternative rapid diagnostic test. Here,
418 specimens were frozen upon arrival to enable subsequent screening with the CRISPR-BP34 test
419 and head-to-head comparison with culture method.

420

421 **Figure 2: Burden of delayed diagnosis on melioidosis treatments and outcomes: A** an UpSet
422 plot summarises the antibiotic prescription when patients were first presented to
423 Sunpasitthiprasong either as a monotherapy or combination therapy. **B** a histogram presents the
424 number of patients who remained undiagnosed at a daily interval following their first presentation
425 or referral to Sunpasitthiprasong Hospital during October 2019 to December 2022. Black arrow
426 denotes the date when a culture-confirmed melioidosis result was available for most patients. **C**
427 summarises choices of antibiotics being prescribed to patients who remained undiagnosed for
428 melioidosis each day following their admission or referral date. Prescription of ceftazidime or
429 carbapenem drugs either as monotherapy or combination therapy are highlighted in blue, with
430 black arrow marking first day presentation.

431

432 **Figure 3: Limit of detection of the CRISPR-BP34 assay and its proposed diagnostic pipeline**
433 **A** and **B** present the limit of the CRISPR-BP34 test detection in blood and urine samples which
434 are the two most common specimens, respectively. The dipsticks were shown as two biological
435 replicates with LOD of urine (50 cfu/mL) and blood (250 cfu/mL). **C** summarises the number of
436 *Burkholderia pseudomallei* that can be recovered from different type of specimens. Green bar
437 indicates the range of limit of detection of the CRISPR test. **D** presents an overview of CRISPR-
438 BP34 diagnosis based on clinical samples including blood, genitourinary fluid, respiratory
439 secretion, pus and other body fluid that were routinely collected from patients suspected of
440 melioidosis. Bacterial pathogen in blood is typically enriched for growth to the detectable
441 threshold (250 cfu/mL) through hemoculture process.

442

443 **Figure 4 Sensitivity and specificity of the culture and the CRISPR approaches**
444 **A** presents combined panels of diagnostic results from 32 patients with multiple specimen types.
445 Top to bottom panels summarise results from hemoculture, genitourinary fluid, respiratory
446 secretion, and pus or other body fluids, respectively. For patients with multiple samples per each
447 sample type, only the first sample was presented. Rows in each panel display results from different
448 diagnostic tests including the gold-standard culture, IFA, latex agglutination, and the CRISPR-
449 BP34 test (top to bottom). Each column corresponds to data from each patient with disease status
450 marked as melioidosis (black) or non-melioidosis (grey). **B** summarises findings from 298 patients
451 with single specimen type with results from hemoculture, genitourinary fluid, respiratory secretion
452 and pus or other body fluids presented in the same order as in (**A**). **C** and **D** compare the sensitivity
453 and specificity of the gold-standard culture and the CRISPR-BP34 approach, respectively. Dots
454 indicate the actual sensitivity or specificity values while the 95% confidence interval are
455 represented by dotted line (culture) and solid line (CRISPR-BP34).
456
457 **Figure 5 Time taken for the culture and the CRISPR-BP34 approaches, and case examples**
458 **A** illustrates the diagnostic time required for the culture and the CRISPR approaches on the log 10
459 scale. **B** to **E** highlighted selected cases (4 of 20 melioidosis cases) where both multiple sample
460 types and multiple specimens per sample type were available (vertical axis). The horizontal axis
461 represents time in days from the date of admission or referral to Sunpasitthiprasong hospital.
462 Circles mark the dates when samples were taken, while rectangles and triangles present the time
463 when the culture-confirmed results and the CRISPR-BP34 results arrived, respectively. For both
464 culture- and CRISPR-BP34 approaches; black denotes negative result, grey highlights detection
465 of other bacterial species than *B. pseudomallei*, while pink (hemoculture), orange (urine), purple
466 (respiratory secretion) and blue (pus, tissue, and other body fluids) present *B. pseudomallei*
467 positive result from each sample type.

468 **Table 1 Demographic of melioidosis patients admitted or referred to Sunpasitthiprasong hospital and survived**
469 **to culture results during October 2019 to December 2022**
470 Significant terms following Benjamini-Hochberg correction for multiple testing were marked with asterisks

	Survive (n = 317)	**Died** (n = 114)	**Total** (n=433)	**raw p-val**	**BH_{adj} p-val**
Age: median (IQR)					
Age in years	53 (45.0 - 61.0)	55 (45.3 - 61.8)	54.00 (45.0 - 61.0)	0.24	0.48
Sex: counts (%)					
Male	223 (70.3%)	81 (71.1%)	306 (70.7%)	1.00	1.00
Occupations: counts (%)					
	Survive	**Died**	**Total**	**raw p-val**	**BH_{adj} p-val**
Agriculture	201 (63.4%)	70 (61.4%)	272 (62.8%)	0.74	0.85
Private sector	55 (17.4%)	21 (18.4%)	76 (17.6)	0.78	0.86
Homemaker	38 (12.0%)	15 (13.2%)	53 (12.3%)	0.74	0.85
Monk	5 (1.6%)	2 (1.8%)	7 (1.6%)	1.00	1.00
Police and Military	4 (1.2%)	2 (1.8%)	6 (1.4%)	0.66	0.85
Distance from patient home to Sunpasitthiprasong hospital in km: median (IQR)					
	Survive	**Died**	**Total**	**raw p-val**	**BH_{adj} p-val**
travel distance	65 (40 - 100)	70 (40 - 100)	65 (40 - 100)	0.17	0.45
Symptoms: counts (%)					
	Survive	**Died**	**Total**	**raw p-val**	**BH_{adj} p-val**
Fever	203 (64.0%)	71 (62.3%)	278 (64.2%)	0.87	0.93
Cough	95 (30.0%)	43 (37.7%)	140 (32.3%)	0.13	0.36
Dyspnea	47 (14.8%)	22 (19.3%)	70 (16.1%)	0.27	0.48
GI disturbance	66 (20.8%)	32 (28.1%)	98 (22.6%)	0.11	0.35
Urinary symptoms	24 (7.6%)	12 (10.5%)	36 (8.3%)	0.33	0.57
Joint pain	26 (8.2%)	3 (2.6%)	29 (6.7%)	0.04	0.19
Muscle pain	44 (13.9%)	13 (11.4%)	57 (13.1%)	0.50	0.74
Local swollen, mass or abscess	34 (10.7%)	5 (4.4%)	39 (9.0%)	0.04	0.19
Weight loss	20 (6.3%)	1 (0.9%)	21 (4.8%)	0.02	0.13
Time to melioidosis diagnosis in days: median (IQR)					
	Survive	**Died**	**Total**	**raw p-val**	**BH_{adj} p-val**
Symptom onset to approaching healthcare*	9.0 (4.0 - 20.0)	6.5 (3.0 - 11.75)	7.0 (3.0 - 14.0)	5.53×10^{-4}	8.57×10^{-3}
refer system	1.0 (0.0 - 4.0)	1.0 (0.0 - 3.0)	1.0 (0.0 - 4.0)	0.67	0.85
sample to culture-diagnosis*	4.0 (3.0 - 6.0)	3.0 (2.0 - 5.0)	4.0 (3.0 - 5.0)	6.24×10^{-3}	0.048

Symptom onset to culture-diagnosis*	18.0 (10.0 - 31.0)	12.0 (7.0 - 19.0)	16.0 (9.0 - 27.0)	5.62×10^{-5}	1.74×10^{-3}

Antibiotics prescription on first presentation to Sunpasitthiprasong: counts (%)

A group of recommended empirical treatment

	Survive	**Died**	**Total**	**raw p-val**	**BH_{adj} p-val**
ceftazidime alone*	44 (13.9%)	5 (4.4%)	49 (11.3%)	5.42×10^{-3}	0.048
carbapenem alone	37 (11.7%)	17 (14.9%)	54 (12.5%)	0.41	0.68
Ceftazidime or carbapenem or both	87 (27.4%)	24 (21.1%)	111 (25.6%)	0.21	0.48
ceftazidime or carbapenem but with other antibiotics	222 (70.0%)	83 (72.8%)	306 (70.7%)	0.63	0.85
no ceftazidime or carbapenem	95 (30.0%)	31 (27.2%)	127 (29.3%)	0.63	0.85

Other antibiotics prescribed on first presentation

	Survive	**Died**	**Total**	**raw p-val**	**BH_{adj} p-val**
ceftriaxone alone or in combination with other antibiotics	70 (22.1%)	34 (29.8%)	100 (23.1%)	0.10	0.35
penicillin alone or in combination with other antibiotics	36 (11.4%)	10 (8.8%)	46 (10.6%)	0.49	0.75
lincosamide alone or in combination with other antibiotics	77 (24.3%)	34 (29.8%)	112 (25.9%)	0.26	0.48
macrolide alone or in combination with other antibiotics	59 (18.6%)	30 (26.3%)	90 (20.8%)	0.10	0.35
nitroimidazole alone or in combination with other antibiotics	27 (8.5%)	14 (12.3%)	41 (9.4%)	0.26	0.48

471

472 **Table 2 Clinical sensitivity and specificity of culture and CRISPR-based methods.**

Sample types	Disease status		Culture-based approach		CRISPR-BP34	
	Melioidosis cases	**Non-melioidosis controls**	**Sensitivity** (Percent, 95% CI)	**Specificity** (Percent, 95% CI)	**Sensitivity** (Percent, 95% CI)	**Specificity** (Percent, 95% CI)
Overall	114	216	76 of 114 (66.7%, CI 57.2 – 75.2%)	216 of 216 (100%, CI 98.3 – 100.0%	106 of 114 (93.0%, CI 86.6 – 96.9%)	209 of 216 (96.8%, CI 93.4 – 98.7%)
Hemoculture	41	74	24 of 41 (58.5%, CI 42.1 – 73.7%)	74 of 74 100%, CI 95.1 – 100.0%)	41 of 41 (100.0%, CI 91.40 – 100.0%)	70 of 74 (94.6%, CI 86.7 – 98.5%)
Genitourinary fluid	27	71	14 of 27 (51.9%, CI 32.0 – 73.3%)	71 of 71 (100%, CI 94.9 – 100.0%)	19 of 27 (70.4%, CI 49.8 – 86.3%)	70 of 71 (98.6%, CI 92.4 – 100%)
Respiratory secretion	52	54	44 of 52 (84.6%, CI 71.9 – 93.1%)	54 of 54 (100%, CI 93.4 – 100.0%)	49 of 52 (94.2%, CI 84.1-98.8%)	53 of 54 (98.2%, CI 90.1-99.6%)
Pus, tissue and other body fluids	15	30	11 of 15 (73.3%, CI 44.9-92.2%)	30 of 30 (100%, CI 88.4 -100.0%)	15 of 15 (100%, CI 78.2 – 100.0%)	29 of 30 (96.67%, CI 82.8-99.9%)

473

References

1 Wiersinga WJ, Virk HS, Torres AG, *et al.* Melioidosis. *Nat Rev Dis Primer* 2018; **4**: 17107.

2 Birnie E, Virk HS, Savelkoel J, *et al.* Global burden of melioidosis in 2015: a systematic review and data synthesis. *Lancet Infect Dis* 2019; **19**: 892–902.

3 Limmathurotsakul D, Golding N, Dance DAB, *et al.* Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nat Microbiol* 2016; **1**: 15008.

4 Savelkoel J, Dance DAB, Currie BJ, Limmathurotsakul D, Wiersinga WJ. A call to action: time to recognise melioidosis as a neglected tropical disease. *Lancet Infect Dis* 2022; **22**: e176–82.

5 Currie BJ, Mayo M, Ward LM, *et al.* The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. *Lancet Infect Dis* 2021; **21**: 1737–46.

6 Mohapatra PR, Mishra B. Burden of melioidosis in India and South Asia: Challenges and ways forward. *Lancet Reg Health - Southeast Asia* 2022; **2**: 100004.

7 Chantratita N, Phunpang R, Yarasai A, *et al.* Characteristics and one year outcomes of melioidosis patients in Northeastern Thailand: A prospective, multicenter cohort study. *Lancet Reg Health - Southeast Asia* 2023; **9**: 100118.

8 Limmathurotsakul D, Jamsen K, Arayawichanont A, *et al.* Defining the True Sensitivity of Culture for the Diagnosis of Melioidosis Using Bayesian Latent Class Models. *PLoS ONE* 2010; **5**: e12485.

9 Peeters M, Ombelet S, Chung P, *et al.* Slow growth of *Burkholderia pseudomallei* compared to other pathogens in an adapted blood culture system in Phnom Penh, Cambodia. *J Med Microbiol* 2019; **68**: 1159–66.

10 Houghton RL, Reed DE, Hubbard MA, *et al.* Development of a Prototype Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis. *PLoS Negl Trop Dis* 2014; **8**: e2727.

11 Tandhavanant S, Wongsuvan G, Wuthiekanun V, *et al.* Monoclonal Antibody-Based Immunofluorescence Microscopy for the Rapid Identification of *Burkholderia pseudomallei* in Clinical Specimens. *Am J Trop Med Hyg* 2013; **89**: 165–8.

12 Lowe W, March JK, Bunnell AJ, O'Neill KL, Robison RA. PCR-based Methodologies Used to Detect and Differentiate the *Burkholderia pseudomallei* complex: *B. pseudomallei*, *B. mallei*, and *B. thailandensis*. *Curr Issues Mol Biol* 2014; **16**: 23–54.

13 Price EP, Dale JL, Cook JM, *et al.* Development and Validation of *Burkholderia pseudomallei*-Specific Real-Time PCR Assays for Clinical, Environmental or Forensic Detection Applications. *PLoS ONE* 2012; **7**: e37723.

14 Novak RT, Glass MB, Gee JE, *et al.* Development and Evaluation of a Real-Time PCR Assay Targeting the Type III Secretion System of *Burkholderia pseudomallei*. *J Clin Microbiol* 2006; **44**: 85–90.

15 Gee JE, Sacchi CT, Glass MB, *et al.* Use of 16S rRNA Gene Sequencing for Rapid Identification and Differentiation of *Burkholderia pseudomallei* and *B. mallei*. *J Clin Microbiol* 2003; **41**: 4647–54.

16 Wongsuvan G, Limmathurotsakul D, Wannapasni S, Chierakul W, Teerawattanasook N, Wuthiekanun V. Lack of correlation of *Burkholderia pseudomallei* quantities in blood, urine, sputum and pus. *Southeast Asian J Trop Med Public Health* 2009; **40**: 781–4.

17 Wuthiekanun V, Limmathurotsakul D, Wongsuvan G, *et al.* Quantitation of *B. Pseudomallei* in clinical samples. *Am J Trop Med Hyg* 2007; **77**: 812–3.

513 18 Fairley L, Smith S, Maisrikrod S, Henning L. Systematic review and meta-analysis of diagnostic tests for
514 diagnosis of melioidosis. *Acta Trop* 2021; **214**: 105784.

515 19 Huang Z, LaCourse SM, Kay AW, *et al.* CRISPR detection of circulating cell-free *Mycobacterium*
516 *tuberculosis* DNA in adults and children, including children with HIV: a molecular diagnostics study. *Lancet*
517 *Microbe* 2022; **3**: e482–92.

518 20 Wongpalee SP, Thananchai H, Chewapreecha C, *et al.* Highly specific and sensitive detection of
519 *Burkholderia pseudomallei* genomic DNA by CRISPR-Cas12a. *PLoS Negl Trop Dis* 2022; **16**: e0010659.

520 21 WHO. Guidelines for the collection of clinical specimens during field investigation of outbreaks. 2000.
521 https://apps.who.int/iris/handle/10665/66348.

522 22 Hinjoy S, Hantrakun V, Kongyu S, *et al.* Melioidosis in Thailand: Present and Future. *Trop Med Infect Dis*
523 2018; **3**: 38.

524 23 Dance D. Treatment and prophylaxis of melioidosis. *Int J Antimicrob Agents* 2014; **43**: 310–8.

525 24 Karunakaran R, Puthucheary SD. *Burkholderia pseudomallei*: In vitro susceptibility to some new and old
526 antimicrobials. *Scand J Infect Dis* 2007; **39**: 858–61.

527 25 Hii SYF, Tandhavanant S, Phunpang R, *et al.* Antibiotic Susceptibility of Clinical *Burkholderia*
528 *pseudomallei* Isolates in Northeast Thailand from 2015 to 2018 and the Genomic Characterization of β -Lactam-
529 Resistant Isolates. *Antimicrob Agents Chemother* 2021; **65**: e02230-20.

530 26 Jenney AWJ, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of *Burkholderia pseudomallei* from
531 tropical northern Australia and implications for therapy of melioidosis. *Int J Antimicrob Agents* 2001; **17**: 109–13.

532 27 Chaowagul W, Simpson AJ, Suputtamongkol Y, White NJ. Empirical cephalosporin treatment of
533 melioidosis. *Clin Infect Dis Off Publ Infect Dis Soc Am* 1999; **28**: 1328.

534 28 Rhodes J, Jorakate P, Makprasert S, *et al.* Population-based bloodstream infection surveillance in rural
535 Thailand, 2007–2014. *BMC Public Health* 2019; **19**: 521.

536 29 An academic meeting to reduce high mortality from melioidosis in the 10th Public Health Region,
537 Thailand. 2023; published online March 2.

538

Figure 1


A
875 melioidosis cases admitted or referred to Sunpasitthiprasong Hospital (day 0) between October 2019 - December 2022
443 excluded
201 died prior to enrollment
- 199 died prior to the arrival of culture confirmed result
- 2 died from covid19
242 alive at time of enrollment
- 120 did not meet enrollment criteria
- 43 discharged or referred prior to enrollment
- 19 did not consent
- 60 hospitalised during the covid19 outbreak
433 enrolled following culture-confirmed positive (day 3 or 4)
317 alive (day 28)
114 died (day 28)
2 unknown (day 28)
B
Clinical samples obtained from 330 patients susepected to have melioidosis at Sunpasitthiprasong Hospital between May 2022 - December 2022
Blood*
melioidosis case = 41
non-melioidosis = 74
Respiratory-secretion
melioidosis case = 52
non-melioidosis = 54
Genitourinary-fluid
melioidosis case = 27
non-melioidosis = 71
Pus & other body fluid
melioidosis case = 15
non-melioidosis = 30
Culture pos = 24/41 neg = 74/74 total = 115
CRISPR pos = 41/41 neg = 70/74 total =115
Culture pos = 44/52 neg = 54/54 total = 106
CRISPR pos = 49/52 neg = 53/54 total = 106
Culture pos = 14/27 neg = 71/71 total = 98
CRISPR pos = 19/27 neg = 70/71 total = 98
Culture pos = 11/15 neg = 30/30 total = 45
CRISPR pos = 15/15 neg = 29/30 total = 45

Figure 2


A
Treatments prescribed on first presentation when culture-confirmed result was not available
Frequency of each monotherapy or combination therapy patients received when first presented to the hospital
nitroimidazole
macrolide
lincosamide
penicillin
ceftriaxone
carbapenem
ceftazidime
Total frequency of antibiotic used at first presentation
A monotherapy of either ceftazidime or carbapenem was recommended for melioidosis
B
Number of patients admitted or referred to the hospital
The majority of patients received culture-confirmed diagnosis on day 4
Date admitted or referred to the hospital
Days patients were left undiagnosed for melioidosis
C
Patients receiving monotherapy of combination therapy with ceftazidime or carbapenem
Proportion of undiagnosed patients being treated by different antibiotics
Ceftazidime or Carbapenem*
Ceftriaxone
Penicillin
Colistin
Lincosamide
Macrolide
Metroinidazole
Limited effectiveness against melioidosis
Resistant to penicillin
Resistant to colistin
Resistant to lincosamide
Resistant to macrolide
Limited effectiveness against melioidosis
Date admitted or referred to the hospital
Days patients were left undiagnosed for melioidosis

CRISPR-cas limit of detection in complex samples



Number of bacterial cells recovered from each specimen type



D Alternative CRISPR-cas12a diagnosis scheme for patient with suspected melioidosis



Figure 4


A Patients with multiple specimen types (index 1-32)
B Patients with single specimen type (index 33 - 330)
patient index 1-32
patient index 33-134
patient index 135-209
patient index 210-292
patient index 293-330
Blood (Hemoculture)
Urine
Respiratory secretion/fluid
Pus/tissue other body fluids
disease
culture
IFA
latex
CRISPR
patient disease status
melioidosis
non-melioidosis
Result
Blood
Urine
Respiratory secretion/fluid
Pus/tissue other body fluid
positive
negative
not performed
Estimate for sensitivity & specificity
Confidence interval for culture
Confidence interval for CRISPR
C Sensitivity
D Specificity
Overall
Hemoculture
Urine
Respiratory secretion
Pus/tissue other body fluid
percent
0
20
40
60
80
100
culture
CRISPR

Figure 5


A
hemoculture
Urine
Respiratory secretion
Pus, tissue other body fluid
Time taken for diagnosis (minutes)
10000
3162
1000
316
100
30
10
6 days
5 days
4 days
3 days
2 days
1 day
culture
CRISPR
B
Earliest CRISPR-confirmed result
Earliest culture-confirmed result
1901-M-393
hemoculture
urine
respiratory secretion
Date from patient admission (days)
C
1901-M-416
D
1901-M-383
pus/ body fluid
E
1901-M-386
date of sample collection
date of culture results
date of CRISPR results
Bp positive
Other species
Bp negative
Hemoculture
Urine
Respiratory secretion
Pus / other body fluids